Zacks Investment Research on MSN
REPL stock soars on plans of BLA resubmission for melanoma combo drug
Shares of Replimune Group REPL soared 85.7% on Friday after the company announced that it had aligned with the FDA on the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...
Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’s ...
) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results